MANKIND
Invest Now
Start SIP in
MANKIND
Performance
- Low
- ₹2,359
- High
- ₹2,468
- 52 Week Low
- ₹1,901
- 52 Week High
- ₹3,055
- Open Price₹2,467
- Previous Close₹2,465
- Volume380,164
Investment Returns
- Over 1 Month -2.94%
- Over 3 Month -3.86%
- Over 6 Month -11%
- Over 1 Year + 0.91%
Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!
Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 48.2
- PEG Ratio
- 2.7
- Market Cap Cr
- 98,433
- P/B Ratio
- 9.3
- Average True Range
- 92.38
- EPS
- 49.48
- Dividend Yield
- 0
- MACD Signal
- 45.36
- RSI
- 43.55
- MFI
- 46.88
Mankind Pharma Financials
Mankind Pharma Technicals
EMA & SMA
Current Price
₹2,385.80
-79.5
(-3.22%)

-
- Bearish Moving Average 15
-
- Bullish Moving Average 1
- 20 Day
- ₹2,474.06
- 50 Day
- ₹2,446.61
- 100 Day
- ₹2,465.87
- 200 Day
- ₹2,429.08
Resistance and Support
2404.17
- R3 2,558.93
- R2 2,513.47
- R1 2,449.63
- S1 2,340.33
- S2 2,294.87
- S3 2,231.03
Mankind Pharma Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-01-23 | Quarterly Results | |
2024-11-05 | Quarterly Results | |
2024-07-31 | Quarterly Results | |
2024-05-15 | Audited Results & Others | To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
2024-01-31 | Quarterly Results |
Mankind Pharma F&O
About Mankind Pharma
- NSE Symbol
- MANKIND
- BSE Symbol
- 543904
- ISIN
- INE634S01028
Similar Stocks to Mankind Pharma
Mankind Pharma FAQs
Mankind Pharma share price is ₹2,385 As on 03 May, 2025 | 03:39
The Market Cap of Mankind Pharma is ₹98433 Cr As on 03 May, 2025 | 03:39
The P/E ratio of Mankind Pharma is 48.2 As on 03 May, 2025 | 03:39
The PB ratio of Mankind Pharma is 9.3 As on 03 May, 2025 | 03:39
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.